Karolinska Institute spinout Aprea Therapeutics has filed to raise approximately $68.3m in an IPO that will see it list on the Nasdaq Global Select Market.
Aprea Therapeutics, a US-based oncological drug developer spun out of Karolinska Institute, has filed for an initial public offering that it hopes will bring in nearly $68.3m in proceeds.
A price range or timeline have not yet been set. Aprea plans to list on the Nasdaq Global Select Market under the ticker symbol APRE.
Incorporated in 2003, Aprea Therapeutics is working on cancer treatments that specifically aim to reactivate the mutant p53 tumour suppressor protein. These mutations occur in a large number of cancers and such patients face a significantly worse prognosis through standard treatments.
Aprea’s lead asset, APR-246, is a late-stage candidate for haematologic malignancies, including acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) – stem cell malignancies that can cause AML – as well as ovarian cancer.
The drug has secured orphan drug designation from the Food and Drug Administration and European Medical…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
